Anna Serefko

Dr. Anna Serefko

Chair and Department of Applied and Social Pharmacy, Medical University of Lublin, 20-093 Lublin, Poland
+1
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in Pharmacological Research
Verified
Journal Article
Open access
KSKatarzyna Socała
Katarzyna Socała
UDUrszula Doboszewska
Urszula Doboszewska
Aleksandra SzopaAleksandra Szopa
Aleksandra Szopa
ASAnna Serefko
Anna Serefko
MWMarcin Włodarczyk
Marcin Włodarczyk
PWPiotr Wlaź
Piotr Wlaź
Emerging evidence indicates that the gut microbiota play a crucial role in the bidirectional communication between the gut and the brain suggesting that the gut microbes may shape neural development, modulate neurotransmission and affect behavior, and thereby contribute to the pathogenesis and/or progression of many neurodevelopmental, neuropsychiatric, and neurological conditions. This review summarizes recent data on the role of microbiota-gut-brain axis in the pathophysiology of neuropsychiatric and neurological disorders including depression, anxiety, schizophrenia, autism spectrum disorders, Parkinson's disease, migraine, and epilepsy. Also, the involvement of microbiota in gut disorders co-existing with neuropsychiatric conditions is highlighted. We discuss data from both in vivo preclinical experiments and clinical reports including: (1) studies in germ-free animals, (2) studies exploring the gut microbiota composition in animal models of diseases or in humans, (3) studies evaluating the effects of probiotic, prebiotic or antibiotic treatment as well as (4) the effects of fecal microbiota transplantation.

11 January 2022 in Metabolites
Verified
Journal Article
Open access
PDF file
MJMonika Elżbieta Jach
Monika Elżbieta Jach
ASAnna Serefko
Anna Serefko
MZMaria Ziaja
Maria Ziaja
Marek KieliszekMarek Kieliszek
Marek Kieliszek
In recent years, the awareness and willingness of consumers to consume healthy food has grown significantly. In order to meet these needs, scientists are looking for innovative methods of food production, which is a source of easily digestible protein with a balanced amino acid composition. Yeast protein biomass (single cell protein, SCP) is a bioavailable product which is obtained when primarily using as a culture medium inexpensive various waste substrates including agricultural and industrial wastes. With the growing population, yeast protein seems to be an attractive alternative to traditional protein sources such as plants and meat. Moreover, yeast protein biomass also contains trace minerals and vitamins including B-group. Thus, using yeast in the production of protein provides both valuable nutrients and enhances purification of wastes. In conclusion, nutritional yeast protein biomass may be the best option for human and animal nutrition with a low environmental footprint. The rapidly evolving SCP production technology and discoveries from the world of biotechnology can make a huge difference in the future for the key improvement of hunger problems and the possibility of improving world food security. On the market of growing demand for cheap and environmentally clean SCP protein with practically unlimited scale of production, it may soon become one of the ingredients of our food. The review article presents the possibilities of protein production by yeast groups with the use of various substrates as well as the safety of yeast protein used as food.

Verified
Journal Article
Open access
PDF file
KSKatarzyna Socała
Katarzyna Socała
Aleksandra SzopaAleksandra Szopa
Aleksandra Szopa
ASAnna Serefko
Anna Serefko
Ewa PoleszakEwa Poleszak
Ewa Poleszak
PWPiotr Wlaź
Piotr Wlaź
Coffee is one of the most widely consumed beverages worldwide. It is usually identified as a stimulant because of a high content of caffeine. However, caffeine is not the only coffee bioactive component. The coffee beverage is in fact a mixture of a number of bioactive compounds such as polyphenols, especially chlorogenic acids (in green beans) and caffeic acid (in roasted coffee beans), alkaloids (caffeine and trigonelline), and the diterpenes (cafestol and kahweol). Extensive research shows that coffee consumption appears to have beneficial effects on human health. Regular coffee intake may protect from many chronic disorders, including cardiovascular disease, type 2 diabetes, obesity, and some types of cancer. Importantly, coffee consumption seems to be also correlated with a decreased risk of developing some neurodegenerative conditions such as Alzheimer’s disease, Parkinson’s disease, and dementia. Regular coffee intake may also reduce the risk of stroke. The mechanism underlying these effects is, however, still poorly understood. This review summarizes the current knowledge on the neuroprotective potential of the main bioactive coffee components, i.e., caffeine, chlorogenic acid, caffeic acid, trigonelline, kahweol, and cafestol. Data from both in vitro and in vivo preclinical experiments, including their potential therapeutic applications, are reviewed and discussed. Epidemiological studies and clinical reports on this matter are also described. Moreover, potential molecular mechanism(s) by which coffee bioactive components may provide neuroprotection are reviewed.

1 May 2013 in Pharmacological Reports
Verified
Journal Article
Closed access
ASAnna Serefko
Anna Serefko
Aleksandra SzopaAleksandra Szopa
Aleksandra Szopa
PWPiotr Wlaź
Piotr Wlaź
GNGabriel Nowak
Gabriel Nowak
MRMaria Radziwoń-Zaleska
Maria Radziwoń-Zaleska
EPEwa Poleszak
Ewa Poleszak

4 April 2023 in Molecules
Verified
Journal Article
Open access
PDF file
MJMonika Elżbieta Jach
Monika Elżbieta Jach
ASAnna Serefko
Anna Serefko
Aleksandra SzopaAleksandra Szopa
Aleksandra Szopa
Ewa SajnagaEwa Sajnaga
Ewa Sajnaga
Hieronim GolczykHieronim Golczyk
Hieronim Golczyk
Elwira SieniawskaElwira Sieniawska
Elwira Sieniawska
Depression is a common and complex mental and emotional disorder that causes disability, morbidity, and quite often mortality around the world. Depression is closely related to several physical and metabolic conditions causing metabolic depression. Studies have indicated that there is a relationship between the intestinal microbiota and the brain, known as the gut–brain axis. While this microbiota–gut–brain connection is disturbed, dysfunctions of the brain, immune system, endocrine system, and gastrointestinal tract occur. Numerous studies show that intestinal dysbiosis characterized by abnormal microbiota and dysfunction of the microbiota–gut–brain axis could be a direct cause of mental and emotional disorders. Traditional treatment of depression includes psychotherapy and pharmacotherapy, and it mainly targets the brain. However, restoration of the intestinal microbiota and functions of the gut–brain axis via using probiotics, their metabolites, prebiotics, and healthy diet may alleviate depressive symptoms. Administration of probiotics labeled as psychobiotics and their metabolites as metabiotics, especially as an adjuvant to antidepressants, improves mental disorders. It is a new approach to the prevention, management, and treatment of mental and emotional illnesses, particularly major depressive disorder and metabolic depression. For the effectiveness of antidepressant therapy, psychobiotics should be administered at a dose higher than 1 billion CFU/day for at least 8 weeks.

Verified
Journal Article
Open access
PDF file
ASAnna Serefko
Anna Serefko
MJMonika Elżbieta Jach
Monika Elżbieta Jach
MPMarlena Pietraszuk
Marlena Pietraszuk
MŚMałgorzata Świąder
Małgorzata Świąder
KŚKatarzyna Świąder
Katarzyna Świąder
Aleksandra SzopaAleksandra Szopa
Aleksandra Szopa
Omega-3 polyunsaturated fatty acids have received considerable attention in the field of mental health, in particular regarding the treatment of depression. This review presents an overview of current research on the role of omega-3 fatty acids in the prevention and treatment of depressive disorders. The existing body of evidence demonstrates that omega-3 fatty acids, in particular eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have antidepressant effects that can be attributed to their modulation of neuroinflammation, neurotransmitter function, and neuroplasticity. Nevertheless, clinical trials of omega-3 supplementation have yielded inconsistent results. Some studies have demonstrated significant reductions in depressive symptoms following omega-3 treatment, whereas others have shown minimal to no beneficial impact. A range of factors, encompassing dosage, the ratio of EPA to DHA, and baseline nutritional status, have been identified as having a potential impact on the noted results. Furthermore, it has been suggested that omega-3 fatty acids may act as an adjunctive treatment for those undergoing antidepressant treatment. Notwithstanding these encouraging findings, discrepancies in study designs and variability in individual responses underscore the necessity of further research in order to establish uniform, standardized guidelines for the use of omega-3 fatty acids in the management of depressive disorders.